PHARMACY

Pfizer, Washington University ink first-of-its-kind deal

BY Alaric DeArment

NEW YORK Pfizer and Washington University plan to work together to find new uses for more than 500 drug compounds under what the drug maker called a first-of-its-kind collaboration between academia and industry.

Pfizer plans to give scientists at the St. Louis-based university’s medical school access to the compounds and research data. The compounds are currently or were formerly in clinical testing. Identifying new uses for existing compounds is called “indications discovery.”

Under the five-year agreement, Pfizer will give the university $22.5 million.

“There are two realities in drug discovery,” Pfizer Indications Discovery Unit chief science officer Don Frail said. “The majority of candidates tested in development do not give the desired result, yet those drugs that do succeed typically have multiple uses. By harnessing the scientific expertise at this leading academic medical center, the collaboration seeks to discover entirely new uses for these compounds in areas of high patient need that might otherwise be left undiscovered.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Teva receives tentative approval for generic Sensipar

BY Alaric DeArment

JERUSALEM The Food and Drug Administration has granted tentative approval to Teva Pharmaceutical Industries’ generic version of an Amgen drug, Teva said Friday.

The FDA gave the tentative approval to cincacalcet hydrochloride tablets in the 30-mg, 60-mg and 90-mg strengths. The drug is a generic version of Amgen’s Sensipar, which has annual sales of $458 million, according to IMS Health. The drug is used to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

Tentative approval means that the drug meets most of the conditions for approval, but the FDA cannot grant final approval because the patents covering the drug don’t expire until December 2016, according to FDA records. Teva and Amgen are currently involved in patent litigation concerning the drug in the U.S. District Court for the District of Delaware, though a trial has not been set, Teva said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

RediClinic introduces Teen Health Package

BY Antoinette Alexander

HOUSTON RediClinic is launching in time for summer camp and upcoming school sports a new health package designed specifically for teenagers.

 

The new Teen Health Package includes a physical exam, an acne consultation and an immunization review for $59.

 

 

"We all know that adolescence is a time of great change," stated Susan Cooley King, VP clinical services. "With this in mind, RediClinic created a special health package that addresses the specific health needs of a teen."

 

 

Physical exams are always in season. They are required by summer camps and for participation in school sports. During a RedlClinic physical, a clinician evaluates the teen’s medical history. The exam is then performed, checking their physical health including, but not limited to, chest and heart, lymph nodes, blood pressure and abdomen.

 

Patients of the Teen Health Package also will receive an evaluation of their acne issues and the clinician will make recommendations for the most appropriate treatment ranging from over-the-counter medications to prescriptions.

 

According to the American Academy of Dermatology, 85% of American teenagers are effected by acne.

 

 

Patients also will receive an immunization review whereby the clinician will review the teen’s immunization history, identify which vaccines the patient needs for school admission and administer the vaccines, for an additional charge if necessary.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?